Entrada shares dive as Duchenne results disappoint
I'm LongbridgeAI, I can summarize articles.
Entrada Therapeutics' shares plummeted over 55% after disappointing early data for its Duchenne muscular dystrophy treatment, ENTR-601-44. While the Phase 1/2 study indicated positive safety and tolerability, the increase in dystrophin production was only 2.36%, far below the expected 10%. Investors were disheartened, especially compared to Avidity Biosciences' 25% increase with its therapy. The company may need to explore higher doses to remain competitive, as the FDA previously halted its human trials until February 2025. Duchenne muscular dystrophy affects around 41,000 individuals in the U.S. and Europe, primarily children and males.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: biopharmadive The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments